Ortho-mcneil Pharmaceutical Corp.

The Scripps Research Institute

Janssen Pharmaceutica Nv

Ortho Pharmaceutical Corporation

Janssen Pharmaceuticals, Inc.

Lars Karlsson

Robin L Thurmond

Per A Peterson

Siquan Sun

James Patrick Edwards

Barbara A Pio

Jianmei Wei

Michael R Jackson

Yin Gu

Susan R Webb

Cheryl A Grice

Steven P Meduna

Ola Winqvist

Haripada Khatuya

Hui Cai

Anne Fourie

Darin J Gustin

Kevin L Tays

Wai-Ping Leung

Sherry Baker

Curt A Dvorak

J Guy Breitenbucher

Chandravadan R Shah

Nicholas I Carruthers

Wenying Chai

Timothy W Lovenberg

Kiev S Ly

Wei Xiao

Jill A Jablonowski

Clark A Sehon

Annette K Kwok

Christopher R Butler

Lubing Zhou

Ola Wingvist

Jennifer D Kreisberg

Siguan Sun

Christopher Alfonso

Fawn Coles

Barbara Pio

The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules with one or more accessory molecules. The matrices are used to activate naive CD4T cells as well as shift the ongoing activation state into a preferred differentiated population of either Th1 or Th2 cells.

[object Object]

A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles.

Method for treating allergies using substituted pyrazoles

The present invention describes synthetic peptide substrates of the metalloproteases, aggrecanase-1 and/or -2 suitable for assays of enzyme activity. The invention also describes methods using these peptides to discover pharmaceutical agents that modulate these proteases.

Aggrecanase-1 and -2 peptide substrates and methods

MHC class II antigen-presenting systems and methods for activatind CD4+T cells

The present invention relates to a method for monitoring the effect of in vivo administration of Cathepsin S inhibitors by measuring accumulation of an intermediate degradation product of invariant chain (Ii), in particular the p10 Ii fragment, in blood of dosed subjects.

Method of monitoring the effect of Cathepsin S inhibitors

Heterocyclic compounds and methods of making them and using them.

Heterocyclic compounds

DNAs encoding monkey cathepsin S have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Polynucleotide and polypeptide sequences of monkey cathepsin S

DNAs encoding canine Cathepsin S have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Polynucleotide and polypeptide sequences of Canine Cathepsin S

A method for the treatment of an allergic condition, including an an atopic allergic conditions, using substituted pyrazoles.

The present invention describes peptide substrates of the metalloproteases, ADAM8, ADAM15 and MDC-L. The invention also describes methods using these peptides to discover pharmaceutical agents that modulate these proteases. The invention further describes CD23 processing activity for these enzymes that may have important therapeutic implications for the use of inhibitors of these enzymes in allergic diseases such as asthma.

Metalloprotease peptide substrates and methods

A transgenic animal with alterations in an H2-O gene is prepared by introduction of an altered H2-O gene into a host animal. The resulting transgenic animals produce a substantially greater frequency of high affinity antibodies compared to H2-O wild type animals. A method for the production of high affinity antibodies is disclosed.

Methods for Producing B cells and antibodies from H2-O modified transgenic mice

Use of cathepsin S inhibitors for the treatment of an allergic condition, in particular an atopic allergic condition, more specifically for the treatment of hay fever, asthma, atopic dermatitis or a food allergy.

Method for treating allergies

The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules with one or more accessory molecules. The matrices are used to activate naive CD4 T cells as well as shift the ongoing activation state into a preferred differentiated population of either Th1 or Th2 cells.

MHC class II antigen-presenting systems and methods for activating CD4&plus; T cells

Growing community of inventors

La Jolla, CA, United States of America

Lars Karlsson